Rituximab for Pediatric Patients with Primary Membranous Nephropathy: Clinical Effectiveness and Cost-Effectiveness
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.